What Is Inflammaging

Inflammaging is a state of chronic, low-grade, sterile inflammation that develops progressively with age in the absence of overt infection. It is characterized by elevated circulating levels of pro-inflammatory cytokines, acute-phase proteins, and other immune mediators that persist at levels too low to trigger clinical symptoms but high enough to damage tissues over decades. The term, coined by immunologist Claudio Franceschi in 2000, captures the intersection of immune system aging and the inflammatory milieu that accompanies it.

Biological aging is not simply wear and tear; it is actively driven by molecular processes, and inflammaging is among the most pervasive of them. The low-grade inflammatory state associated with aging has been linked to virtually every major chronic disease, including atherosclerosis, neurodegeneration, insulin resistance, and cancer. Because inflammaging operates systemically, it does not confine its damage to one organ. Instead, it creates an environment where cellular repair slows, tissue regeneration falters, and immune surveillance becomes less precise.

For longevity, inflammaging matters because it represents a modifiable driver of biological aging. Unlike chronological age, the degree of systemic inflammation can be influenced by diet, exercise, sleep, body composition, and emerging pharmacological strategies. Understanding inflammaging shifts the focus from treating individual age-related diseases after they appear to addressing the shared inflammatory substrate that fosters their development.

The mechanisms behind inflammaging are layered and self-reinforcing. At the cellular level, aging tissues accumulate senescent cells, which are cells that have permanently exited the cell cycle but resist apoptosis. These senescent cells secrete a cocktail of pro-inflammatory cytokines, chemokines, and matrix metalloproteinases collectively known as the senescence-associated secretory phenotype (SASP). The SASP creates a local inflammatory microenvironment that can spread to neighboring tissues, recruiting immune cells and inducing further senescence in a paracrine fashion.

The aging immune system itself is a major contributor. Immunosenescence, the progressive decline of immune function, leads to impaired clearance of damaged cells, pathogens, and debris. Thymic involution reduces naive T-cell output, while memory and effector T-cell populations become skewed and chronically activated. Macrophages shift toward a more pro-inflammatory phenotype. The net result is an immune system that is simultaneously less effective at targeted defense and more prone to nonspecific inflammatory signaling.

Mitochondrial dysfunction adds a third layer. As mitochondria age, they release damage-associated molecular patterns (DAMPs), including mitochondrial DNA fragments and reactive oxygen species, which activate innate immune sensors such as the NLRP3 inflammasome and the cGAS-STING pathway. Gut barrier integrity also declines with age, allowing microbial products to translocate into systemic circulation and activate toll-like receptors on immune cells. These inputs converge on the NF-kB signaling pathway, the master transcriptional regulator of inflammatory gene expression, keeping it chronically active. Visceral adipose tissue, which tends to expand with age, produces its own inflammatory mediators, adding further fuel to the cycle.

Inflammaging has moved from a conceptual framework in geroscience to a measurable target in clinical research. Multiple academic centers and longevity-focused clinical programs now include inflammatory biomarker panels as standard elements of aging assessments. The development of epigenetic clocks that incorporate inflammatory signatures, such as the GrimAge clock, has linked inflammaging to objective measures of biological age acceleration. Clinical trials are underway testing senolytics (drugs that clear senescent cells), mTOR inhibitors, and anti-inflammatory biologics specifically for their effects on the inflammaging phenotype.

However, clinical consensus on how to define, measure, and intervene on inflammaging remains absent. There is no standardized diagnostic panel, no agreed-upon threshold for treatment, and no approved pharmaceutical specifically targeting inflammaging. The field occupies a space where the biological rationale is strong, the epidemiological associations are consistent, and the therapeutic toolkit is still being assembled.

Assessment of inflammaging is broadly accessible through standard laboratory testing. hsCRP, IL-6, and fasting insulin can be ordered through conventional physicians or direct-to-consumer blood testing services. More specialized markers like TNF-alpha, fibrinogen, and homocysteine are available through functional medicine and longevity clinic panels. GlycanAge and epigenetic clock testing services are commercially available, though at higher cost and with varying levels of validation.

Lifestyle interventions for inflammaging, including dietary modification, exercise, sleep optimization, and stress management, require no prescription and are universally accessible. Targeted supplements such as omega-3 fatty acids, curcumin, and quercetin are widely available over the counter. More advanced interventions like senolytic protocols, low-dose rapamycin, or metformin used off-label for anti-inflammatory aging effects are accessible primarily through longevity medicine clinics, functional medicine practitioners, or clinical trials.

Inflammaging may emerge as one of the most actionable targets in longevity medicine precisely because it sits upstream of so many age-related diseases. If interventions can meaningfully reduce the systemic inflammatory burden of aging, the downstream effects could extend across cardiovascular, metabolic, neurological, and musculoskeletal systems simultaneously. This makes inflammaging a high-leverage node in the biology of aging.

Several converging research trajectories make this field worth watching. Senolytic drugs are advancing through human trials, with results expected to clarify whether clearing senescent cells reduces inflammaging in practice. Advances in multi-omics profiling may enable personalized inflammaging signatures that guide individualized interventions rather than population-level recommendations. The integration of continuous biomarker monitoring through wearable and at-home testing platforms could make longitudinal tracking of inflammatory status routine rather than episodic. If these threads come together, inflammaging could shift from an academic concept to a primary axis of preventive care.

The concept of inflammaging is supported by extensive epidemiological evidence linking elevated inflammatory biomarkers in older adults to increased mortality, cardiovascular events, cognitive decline, and frailty. Large prospective cohort studies have consistently shown that higher hsCRP and IL-6 levels predict all-cause mortality independently of traditional risk factors. Centenarian studies have observed that those who reach extreme old age tend to exhibit lower inflammatory profiles, or effective anti-inflammatory compensatory mechanisms, compared to age-matched peers who develop disease.

Mechanistic research in animal models has clarified several pathways. Genetic ablation of senescent cells in mice reduces inflammatory markers and extends healthspan, supporting the SASP as a driver of inflammaging. Caloric restriction and rapamycin, both of which suppress mTOR signaling, reduce inflammatory cytokine levels in multiple model organisms. Human intervention trials on exercise, Mediterranean dietary patterns, and omega-3 supplementation have shown measurable reductions in circulating inflammatory markers, though the degree to which these changes translate into hard disease endpoints over decades remains difficult to quantify. The field still lacks a standardized inflammaging index, and individual variation in immune aging makes population-level findings difficult to apply at a personal level.

Inflammaging is a descriptive framework rather than a defined clinical diagnosis, so there is a risk of over-interpreting single biomarker readings without considering context, acute illness, or measurement variability. Aggressively suppressing inflammation through pharmacological means carries its own hazards, as the immune system requires some inflammatory capacity for infection defense, wound healing, and tumor surveillance. Anti-inflammatory compounds, whether prescription or over-the-counter, can have side effects ranging from gastrointestinal damage to immune suppression when used chronically. Individuals with autoimmune conditions, active infections, or those on immunosuppressive therapy should work with a clinician before layering additional anti-inflammatory strategies.